| Latest in vitro and in vivo models of celiac disease. | |
| | |
MedLine Citation:
|
PMID: 23293929 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Introduction: Currently, the only treatment for celiac disease is a gluten-free diet, and there is an increased desire for alternative therapies. In vitro and in vivo models of celiac disease have been generated in order to better understand the pathogenesis of celiac disease, and this review will discuss these models as well as the testing of alternative therapies using these models. Areas covered: The research discussed describes the different in vitro and in vivo models of celiac disease that currently exist and how they have contributed to our understanding of how gluten can stimulate both innate and adaptive immune responses in celiac patients. We also provide a summary on the alternative therapies that have been tested with these models and discuss whether subsequent clinical trials were done based on these tests done with these models of celiac disease. Expert opinion: Only a few of the alternative therapies that have been tested with animal models have gone on to clinical trials; however, those that did go on to clinical trial have provided promising results from a safety standpoint. Further trials are required to determine if some of these therapies may serve as an effective adjunct to a gluten-free diet to alleviate the adverse affects associated with accidental gluten exposure. A "magic-bullet" approach may not be the answer to celiac disease, but possibly a future cocktail of these different therapeutics may allow celiac patients to consume an unrestricted diet. |
| | |
Authors:
|
Samantha Stoven; Joseph A Murray; Eric V Marietta |
Related Documents
:
|
21253289 - Case reports on two patients with episodic vertigo, fluctuating hearing loss and migrai... 21211479 - Communicable diseases report, nsw, july and august 2010. 23642059 - Differences between parkinson's and huntington's diseases and their role for prioritiza... 21465139 - Mechanisms and potential therapies for preeclampsia. 14596709 - The influence of perceived control over causes and responses to health threats: a vigne... 22672419 - Treating scars: addressing surface, volume, and movement to expedite optimal results. p... 15188509 - Severity of gastroesophageal reflux disease influences daytime somnolence: a clinical s... 23272689 - Advances and challenges in the dosage form design for the treatment of parkinson's dise... 8386329 - Transmembrane signaling through phospholipase c in human cortical membranes. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2013-1-8 |
Journal Detail:
|
Title: Expert opinion on drug discovery Volume: - ISSN: 1746-045X ISO Abbreviation: Expert Opin Drug Discov Publication Date: 2013 Jan |
Date Detail:
|
Created Date: 2013-1-8 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101295755 Medline TA: Expert Opin Drug Discov Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Mayo Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic Rochester , 200 first St. SW, Rochester, 55905 , USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Waitlist characteristics of patients at a single-center intestinal and multivisceral transplant prog...
Next Document: Chromium(VI) but not Chromium(III) Species Decrease Mitoxantrone Affinity to DNA.